However, appropriate analyses seem to be advisable, since inflammation is an important component of tumor progression [33], and elevated plasma levels of IL-1β have been found in patients with both small cell lung cancer and NSCLC [34]. This evidence concerns the gene IL1B and non-small cell lung carcinoma.